INTRODUCTION: We develop a multiplex quantitative real-time PCR for synchronized analysis of mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) to investigate relative mtDNA abundance in paired normal and cancerous breast tissues. MATERIALS AND METHODS: The amounts of nDNA and mtDNA in 102 tissue samples were quantified for both glyceraldehype-3-phosphodehydrogenase (GAPDH) gene and mtDNA encoded ATPase (MTATP) 8 gene. The average threshold cycle (Ct) number values of the nDNA and mtDNA were used to calculate relative mtDNA content in breast tissues. RESULTS: The median delta Ct (DeltaCt) and the median mtDNA content for normal and cancerous breast tissues were 6.73 and 2.54, as well as 106.50 and 5.80 (P = 0.000, respectively). The mtDNA content was decreased in 82% of cancerous breast tissues compared with the normal ones. The changes were associated with hormone receptor status. CONCLUSION: Our finding suggests that decreased mtDNA content in breast cancer may have diagnostic and prognostic value for the disease.
INTRODUCTION: We develop a multiplex quantitative real-time PCR for synchronized analysis of mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) to investigate relative mtDNA abundance in paired normal and cancerous breast tissues. MATERIALS AND METHODS: The amounts of nDNA and mtDNA in 102 tissue samples were quantified for both glyceraldehype-3-phosphodehydrogenase (GAPDH) gene and mtDNA encoded ATPase (MTATP) 8 gene. The average threshold cycle (Ct) number values of the nDNA and mtDNA were used to calculate relative mtDNA content in breast tissues. RESULTS: The median delta Ct (DeltaCt) and the median mtDNA content for normal and cancerous breast tissues were 6.73 and 2.54, as well as 106.50 and 5.80 (P = 0.000, respectively). The mtDNA content was decreased in 82% of cancerous breast tissues compared with the normal ones. The changes were associated with hormone receptor status. CONCLUSION: Our finding suggests that decreased mtDNA content in breast cancer may have diagnostic and prognostic value for the disease.
Authors: Ana Mosquera-Miguel; Vanesa Alvarez-Iglesias; Angel Carracedo; Antonio Salas; Ana Vega; Angel Carracedo; Roger Milne; Antonio Cabrera de León; Javier Benitez; Angel Carracedo; Antonio Salas Journal: Cancer Res Date: 2008-01-15 Impact factor: 12.701
Authors: Elizabeth Mambo; Aditi Chatterjee; Mingzhao Xing; Giovanni Tallini; Bryan R Haugen; Sai-Ching J Yeung; Saraswati Sukumar; David Sidransky Journal: Int J Cancer Date: 2005-10-10 Impact factor: 7.396
Authors: Takahiro Yamazaki; Alexander Kirchmair; Ai Sato; Aitziber Buqué; Marissa Rybstein; Giulia Petroni; Norma Bloy; Francesca Finotello; Lena Stafford; Esther Navarro Manzano; Francisco Ayala de la Peña; Elena García-Martínez; Silvia C Formenti; Zlatko Trajanoski; Lorenzo Galluzzi Journal: Nat Immunol Date: 2020-08-03 Impact factor: 25.606
Authors: S Masuda; T Kadowaki; N Kumaki; X Tang; Y Tokuda; S Yoshimura; S Takekoshi; R Y Osamura Journal: Br J Cancer Date: 2012-11-20 Impact factor: 7.640